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Full-length soluble urokinase 
plasminogen activator receptor 
down-modulates nephrin 
expression in podocytes
Massimo Alfano1, Paola Cinque2, Guido Giusti3, Silvia Proietti3, Manuela Nebuloni4, 
Silvio Danese5, Silvia D’Alessio5, Marco Genua5, Federica Portale6, Manuela Lo Porto6, 
Pravin C. Singhal7, Maria Pia Rastaldi8, Moin A. Saleem9, Domenico Mavilio6,10,* & 
Joanna Mikulak6,*
Increased plasma level of soluble urokinase-type plasminogen activator receptor (suPAR) was 
associated recently with focal segmental glomerulosclerosis (FSGS). In addition, different clinical 
studies observed increased concentration of suPAR in various glomerular diseases and in other 
human pathologies with nephrotic syndromes such as HIV and Hantavirus infection, diabetes 
and cardiovascular disorders. Here, we show that suPAR induces nephrin down-modulation in 
human podocytes. This phenomenon is mediated only by full-length suPAR, is time-and dose-
dependent and is associated with the suppression of Wilms’ tumor 1 (WT-1) transcription factor 
expression. Moreover, an antagonist of αvβ3 integrin RGDfv blocked suPAR-induced suppression 
of nephrin. These in vitro data were confirmed in an in vivo uPAR knock out Plaur−/− mice model 
by demonstrating that the infusion of suPAR inhibits expression of nephrin and WT-1 in podocytes 
and induces proteinuria. This study unveiled that interaction of full-length suPAR with αvβ3 integrin 
expressed on podocytes results in down-modulation of nephrin that may affect kidney functionality 
in different human pathologies characterized by increased concentration of suPAR.
Release of the urokinase-type plasminogen activator receptor (uPAR, encoded by PLAUR), is catalyzed 
by various enzymes and results in soluble uPAR (suPAR) that can be shed from cell membrane either 
in full-length suPAR (fl-suPAR) or cleaved variants (c-suPAR) thus generating different suPAR isoforms 
with different functions1–7. Both fl-suPAR and c-suPAR binding to its ligand uPA mediate a scavenger 
activity and interact with cell associated integrins in order to influence different intracellular processes3. 
Although the function(s) of c-suPAR variant is only partially known, there is evidence that this cleaved 
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form of the protein acquires chemotactic activity by either favoring mobilization of hematopoietic stem 
cells from bone marrow or by inhibiting the chemotactic potential of the chemokine-enriched extracel-
lular milieu of HIV-infected tonsils4–6.
Recently, the increased concentration of suPAR was proposed as a specific circulating risk factor for 
Focal Segmental Glomerusclerosis (FSGS)8. However, further clinical studies observed increased concen-
tration of suPAR also in other glomerular and proteinuric disease indicating that plasma suPAR accumu-
lation is not a specific biomarker for FSGS but increases also in other glomerular disorders characterized 
by decreased glomerular filtration rate (GFR) and in some cases by proteinuria9–13. Furthermore, high 
plasma levels of suPAR have been associated with the progression of diverse human pathologies includ-
ing cancer, sepsis, liver disease, rheumatic disorders and HIV infection, sharing systemic degrees of 
inflammation and chronic immune activation14–21.
Podocytes are highly specialized epithelial cells that have an important function in the process of 
glomerular barrier filtration together with fenestrated endothelium and glomerular basement membrane. 
Various proteins including nephrin, synthesized by the podocytes are integral parts of the slit diaphragm 
and are required for the proper functioning of the renal filtration barrier. Different identified nephrin 
gene mutations and defects of nephrin distribution at the level of the slit diaphragm cause congenital 
nephritic syndromes22–24 and proteinuria25–27, respectively. Moreover, integrins in kidney play a critical 
role in development, homeostasis and renal diseases28,29. Recently α vβ 3 integrin expressed on podo-
cytes has been proposed as a suPAR binding molecule regulating the glomerular filtration barrier30–33. 
However, the mechanistic insight(s) associated to podocyte dysfunction mediated by suPAR- α vβ 3 inter-
action have not yet been disclosed. Because of their ability to interact with cellular transmembrane 
receptors, full length suPAR and c-suPAR are not only mere biomarkers of disease progression, but 
may also be actively involved in their pathogenesis. The present study shows that both recombinant and 
plasma associated suPAR down-modulate nephrin at transcription and protein levels in human podo-
cytes in vitro. Furthermore, we demonstrated that only the full-length form, but not c-suPAR variant, is 
associated with the negative modulation of nephrin through a direct interaction with α vβ 3 integrin. This 
mechanism was further supported by an in vivo model of suPAR knock out (Plaur−/−) mouse showing 
that the infusion of high dose of suPAR inhibits expression of nephrin and Wilms’ tumor 1 (WT-1) in 
podocytes and induces proteinuria indicating that the full length suPAR might actively contribute to the 
podocytes dysfunction in different human pathologies.
Results
SuPAR induces down-modulation of nephrin in human primary podocytes. Various, genetic 
and functional, nephrin defects lead to nephritic syndromes and proteinuria22–27. To verify the effect 
of suPAR stimulation on nephrin expression, we used human primary podocytes obtained from renal 
tissue of patients affected by renal adenocarcinoma who underwent a radical nephrectomy. All tissue 
specimens used for this study were collected from the distal part of the pathological tissue and were 
free from any disease as was verified by haematoxylin-eosin-staining (Fig. 1a). We then cultured freshly 
isolated glomerula in order to obtain human podocytes (Fig. 1a), whose phenotype was verified by qPCR 
analysis detecting gene expression of the following specific podocytes markers: Wilms’ tumor 1 (WT-1), 
synaptopodin, nephrin and podocin (data not shown). Mean serum and plasma concentration of suPAR 
in healthy adults have been reported to be 2 ng/mL18, whereas it reaches 20 ng/mL in patients with var-
ious diseases, such as cancer, sepsis, liver disease, HIV infection and FSGS8,14,18–21. We then proceeded 
to incubate human primary podocytes with 20 ng/mL of human recombinant fl-suPAR. After 24 hours 
of stimulation we detected by fluorescence microscopy a significant down-modulation of nephrin at the 
protein level (Fig. 1b). Immunoflourescence staining of frozen tissue from human normal kidney served 
to confirm the specificity of anti-nephrin rabbit clonal antibody (Ab) used for this study (Fig. 1c). The 
decreased amount of nephrin following incubation of primary podocytes with suPAR was also con-
firmed by qPCR, thus suggesting a transcriptional control of nephrin expression by suPAR (Fig. 1d). To 
both confirm the modulation of nephrin exerted by suPAR and to disclose the related mechanism in a 
post-mitotic podocyte, we repeated the same experimental approach in conditional immortalized human 
podocytes (CIHPs) in vitro34. By performing assessments of protein expression with immune-floures-
cence in CIHPs incubated with different concentrations of suPAR for 24 hours, we detected a significant 
reduction of nephrin flourescence intensity and thus a lower level of nephrin protein in suPAR stimu-
lated CIHPs comparing to control experiments, with the maximum inhibition between 10–20 ng/mL of 
suPAR (Fig. 2a). To determine whether suPAR stimulation affects nephrin expression at the transcrip-
tional level, we performed qPCR experiments. As shown in Fig.  2b, quantification of nephrin mRNA 
in CIHPs incubated with suPAR showed a rapid and progressive decrease of Nephrin gene expression 
(Fig. 2a–c). The reduction of nephrin transcripts was already detectable after 3 hours and became signif-
icant after 6 hours of treatment, when it also reached a plateau that was maintained even after 24 hours 
of stimulation. However, we did not observe any significant suPAR-mediated down-modulation of the 
expression of synaptopodin, another specific podocyte marker, thus indicating the specificity of suPAR 
in suppressing nephrin expression in CIHPs (Fig. 2c).
Full-length suPAR, but not the truncated variant, down-regulates nephrin expression in 
human podocytes. Structurally, uPAR is a GPI-anchored membrane glycoprotein consisting of 
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three homologous domains (DIDIIDIII)35. Cleavage of uPAR from the cell membrane is catalyzed by var-
ious enzymes and can occur both at the GPI-anchor and the linker region between DI and DII. The 
suPAR resulting from cleavage may thus consist of domain DIDIIDIII, DIIDIII or DI. Since the increased 
level of plasma-associated suPAR in human disorders reflects the increased concentration of both 
DIDIIDIII (fl-suPAR) and DIIDIII (c-suPAR) variants, we evaluated the contribution of suPAR variants 
in down-modulation of nephrin in CIHPs4,6. To compare the dose-dependent effects of fl-suPAR and 
c-suPAR variants on nephrin inhibition, two suPAR variants were tested in the range of concentration 
between 0.4–0.02 nM that resulted with the previously observed maximum inhibitory effect of fl-suPAR 
(Fig.  2b). Interestingly, only fl-suPAR protein was able to significantly reduce nephrin expression at 
transcription level (Fig.  3a). In addition immunoflourescence analysis showed a statistically significant 
reduction of nephrin also at protein level only after stimulation with fl-suPAR and not with its short 
Figure 1. SuPAR down-modulates nephrin expression in human primary podocytes. (a) Haematoxylin-
eosin-staining (left picture) of human kidney from patients underwent to nephrectomy due to the renal 
cell carcinoma. Isolated human glomerula were cultured in vitro in order to obtain human primary 
podocytes (right picture). One representative experiment out of 20 is shown. (b) Quantification (left panel) 
of the immunoflourescence staining of nephrin expression in control (Mock) and human primary isolated 
podocytes treated with human recombinant suPAR (20 ng/mL) for 24 hours (suPAR). Results are expressed 
as MFI/cell and represent the average of 3 experiments ± SD. DAPI staining was used to determine nuclei 
number. Right picture represent one representative experiment out of 3 of nephrin expression in green (488 
Alexa Fluor) in Mock and suPAR treated human primary podocytes. A nucleus staining is show in blue 
(DAPI). (c) Immunoflourescence staining of frozen tissue from human normal kidney with the specific 
clonal rabbit anti-nephrin Ab (488 Alexa Fluor). (d) QPCR analysis of nephrin expression by using specific 
human TaqMan assay in Mock and suPAR treated human podocytes. Results are expressed as relative fold 
change in suPAR treated cells vs Mock cells (Δ Δ Ct) and represent the average of 3 experiments ± SD. 
Values were normalized to GAPDH gene expression. Statistical significance (P) is indicated by asterisks and 
is represented as: **< 0.01; ***< 0.001.
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Figure 2. Down-modulation of nephrin expression both at protein and transcription level in CIHPs. 
(a) Quantification (left panel) of immunoflourescence staining (right upper panel) of nephrin expression 
in control (Mock) and CIHPs treated with different human recombinant suPAR for 24 hours (suPAR). 
Results are expressed as MFI/cell and represent the average of 6 experiments ± SD. DAPI staining was used 
to determine nuclei number. Results are expressed as MFI/cell and represent the average of 4 experiments 
± SD. Right picture shows one representative immunoflourescence staining out of 4 of nephrin expression 
(488 Alexa Fluor) in green and nucleus (DAPI) in blue. (b) Dose-dependent qPCR analysis of nephrin 
expression in Mock and suPAR treated human podocytes by using specific human TaqMan assays. Results 
are expressed as relative fold change in suPAR treated cells vs Mock cells (Δ Δ Ct) and represent the average 
of 6 experiments ± SD. Values were normalized to the expression of GAPDH gene. (c) Time course qPCR 
analysis of nephrin and synaptopodin expression in Mock and suPAR treated human podocytes by using 
specific human TaqMan assays. Results are expressed as relative fold change in suPAR treated cells vs Mock 
cells (Δ Δ Ct) and represent the average of 6 experiments ± SD. Values were normalized to the expression of 
GAPDH gene. Statistical significance (P) is indicated by asterisks and is represented as: ***< 0.001.
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variant c-suPAR (Fig.  3b). These data provide strong evidences of fl-suPAR and not c-suPAR variant 
capability to induce nephrin down-regulation in human podocytes.
SuPAR mediated down-regulation of nephrin in human podocytes occurs through interaction 
with αvβ3 integrin and is associated with suppression of the WT-1 transcription factor. It 
has been demonstrated that suPAR binds and activates α vβ 3 integrin in human podocytes8. In order 
to understand whether the α vβ 3 integrin molecule is involved in suPAR dependent down-regulation of 
nephrin we used the α vβ 3 small molecule-inhibitor cycloRGDfv8. Pre-treatment of CIHPs constitutively 
expressing α vβ 3 integrin with cycloRGDfv prior stimulation with fl-suPAR resulted in a significant inhi-
bition of suPAR-dependent downmodulation of nephrin at the transcription level (Fig.  4a). Moreover, 
qPCR analysis revealed that the effect of cycloRGDfv on nephrin expression on CIHPs incubated with 
suPAR is dose dependent, since incubation with 5 μ M and 10 μ M of this α vβ 3 inhibitor, respectively, par-
tially or fully restored the amount of nephrin transcripts compared to control experiments. These find-
ings suggest that suPAR is able to induce the down-modulation of nephrin in CIHPs via α vβ 3 interaction
Different activating and suppressing transcription factors have been identified as being involved in 
the transcriptional regulation of Nephrin gene expression36–38. The most documented transcription factor 
Figure 3. Full length DIDIIDIII suPAR down-regulates nephrin expression in CIHPs. (a) QPCR analysis 
using specific human nephrin TaqMan assay in Mock and treated human podocytes with different 
concentration of full lengh suPAR (fl-suPAR) or short suPAR (c-suPAR) variants of suPAR. Results are 
expressed as relative fold change in suPAR treated cells vs Mock cells (Δ Δ Ct) and normalized to the 
expression of GAPDH gene. Results are represent as the average of 3 independent experiments ± SD.  
(b) Quantification of immunoflourescence staining (left panel) of nephrin expression in control (Mock) 
and treated human podocytes for 24 hours with 0.4 nM of the full-length (fl-suPAR) or cleaved (c-suPAR) 
variants of suPAR. Results are expressed as MFI/cell and represent the average of 3 experiments ± SD. 
Right picture shows one representative immunoflourescence staining out of 3 of nephrin expression (488 
Alexa Fluor) in green and nucleus (DAPI) in blue.Statistical significance (P) is indicated by asterisks and is 
represented as: **< 0.01; ***< 0.001.
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involved in the regulation of Nphs1 gene expression is WT-1. Knockout, transgenic, and siRNA analyses 
have demonstrated the importance of WT-1 at several stages of kidney development39–41. Moreover, 
expression of WT-1 continues in podocytes of adult kidneys and is required for physiological levels of 
nephrin expression. Consistent with this observation, it was demonstrated that nephrin expression in 
podocytes is lower in the kidneys of mice with reduced expression of WT-137,42. In addition, both in vitro 
and in vivo functional approaches have shown that WT-1 can bind and activate the nephrin promoter 
and that this binding is essential for nephrin-specific expression in vivo37,43. Since our results showed 
suPAR-dependent down-regulation of nephrin at transcription level, we assessed whether WT-1 is 
involved in this process. QPCR analysis of WT-1 transcription showed a statistically significant decrease 
of WT-1 expression in CIHPs after treatment with fl-suPAR (Fig.  4b), thus indicating that WT-1 is a 
possible target of an activated suPAR-α vβ 3 signaling down-stream pathway. In line with the kinetic 
observed for the down-modulation of nephrin (Fig. 4a), experiments performed with different concen-
trations of cycloRGDfv inhibitor revealed a full restoration of WT-1 transcripts after pre-treatment with 
10 μ M of cycloRGDfv (Fig. 4b), while we still could observe a lower but significant inhibition of nephrin 
incubating CIHPs with 5 μ M of the α vβ 3 inhibitor. To assess the specific suPAR-dependent attenuating 
role of WT-1 transcription factor in nephrin gene expression we evaluated the binding of WT-1 in the 
promoter region of Nphs1 by chromatin immunoprecipitation assay (ChIP). We detected a significantly 
lower binding of WT-1 protein in the regulatory region of Nphs1 gene in fl-suPAR treated cells compared 
to the non-stimulated podocytes (Fig.  5a). Amplification of GAPDH promoter was used as a positive 
control in CIHPs by immunoprecipitation of chromatin with anti-RNA polymerase II antibody (Fig. 5b). 
GAPDH promoter is lacking any WT-1 site thus as a negative control we amplified GAPDH promoter 
after chromatin immunoprecipitation with IgG or anti-WT-1 antibody in Mock and suPAR treated 
Figure 4. SuPAR mediated down-regulation of nephrin depends on αvβ3 integrin interaction and is 
associated with reduced activity of WT-1. (a–b) Quantification of qPCR analysis of nephrin (a) and WT-1 
(b) expression in Mock and suPAR treated (20 ng/mL) for 24 hours in CIHPs pre-incubated with different 
concentration (1, 5 and 10 μ M) of α vβ 3 antagonist (RGDfv). Results obtained by using the specify human 
TaqMan assays are expressed as relative fold change in treated cells vs. mock cells (Δ Δ Ct) and represent 
the average of 3 independent experiments ± SD. Values were normalized to the expression of GAPDH gene. 
Right upper picture of panel A shows one representative immunoflourescence staining out of 3 of α vβ 3 (594 
Alexa Fluor) integrin expression in red and nucleus in blue (DAPI) in CIHPs.
www.nature.com/scientificreports/
7Scientific RepoRts | 5:13647 | DOi: 10.1038/srep13647
samples, however, we did not observe any significant changes (Fig.  5b). Specificity of the anti-WT-1 
antibody used in ChIP assay was tested in the Jurkat and in K562 cell lines, known to be respectively 
negative and positive cells for WT-1 expression (Fig.  5c–d)44,45. These data strongly indicate that the 
suPAR-dependent down regulation of nephrin might occur through decreased transcription levels of 
WT-1 factor resulting in the attenuated binding to Nphs1 gene promoter and thus lower transcription 
of nephrin. In addition, we analyzed the expression of the transcription regulator Snail that has recently 
been proposed as a repressor of Nephrin gene expression38. However, although we found detectable levels 
Figure 5. SuPAR induces lower WT-1 binding to the Nephrin gene promoter. (a) Chromatin 
immunoprecipitation (ChIP) analysis of WT-1 binding to the cis region of Nphs1 gene promoter in CIHPs. 
Results are represented as fold change in the enrichment of precipitated chromatin fragments of Nphs1 gene 
promoter with either anti-WT-1 Ab or Rabbit Normal IgG in non treated (Mock) or treated with suPAR 
cells. Precipitated products were amplified by qPCR by using SYBR Green assay and normalized to DNA 
lacking any WT-1 site, located in the promoter of GAPDH gene of Input. (b) Binding of the specific anti-
RNA polymerase II (CTD4H8) Ab to the DNA fragment of GAPDH gene was used as the positive control 
(Ctrl). Amplification of GAPDH gene promoter in the IgG and WT-1 chromatin immunoprecipitated of 
Mock and su-PAR treated samples were used as a negative Ctrl. ChIP samples were analyzed in triplicate 
and represented the average of 3 independent experiments ± SD. (c) QPCR analysis of WT-1 gene expression 
in Jurkat and K562 and CIHPs cell lines. TaqMan assays of 3 independent experiments ± SD. Values were 
normalized to the expression of GAPDH gene. (d) Detection of WT-1 protein by Western blotting assay 
(WB) after the chromatin immunoprecipitation with IgG control or anti-WT-1 antibodies in Jurkat and 
K562 cells. Analysis of β -actin of Inputs were used for normalization. One representative cropped blot out 
of two is shown. Statistical significance (P) is indicated by asterisks and is represented as: *< 0.05; **< 0.01; 
***< 0.001.
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of Snail in CIHPs, we did not measure any increased amount of Snail after suPAR treatment (data not 
shown).
High-dose of suPAR in knock out Plaur−/− mice inhibits nephrin and WT-1 expression in podo-
cytes and induces proteinuria. We next examined whether exogenous circulating full-length suPAR 
could cause nephrin down-modulation in uPAR-knockout (Plaur−/−) mice in which we injected i.v. 20 μ g 
(1 mg/Kg) of murine full-length recombinant mouse suPAR. After 24 hours, we observed an increased 
level of proteinuria and higher amount of suPAR deposit in the glomeruli of Plaur−/− mice infused 
with full-length recombinant murine suPAR compared to control experiments (Fig. 6a)8. Moreover, we 
performed experiments using confocal microscopy in the same experimental setting and we observed a 
significant down-modulation of nephrin expression with no changes in synaptopodin levels in Plaur−/− 
mice infused with full-length recombinant murine suPAR compared to control experiments (Fig.  6b). 
Finally, we confirmed our results obtained in vitro in the in vivo model by showing that the decreased 
expression of nephrin is associated with the down-modulation of WT-1 in suPAR treated Plaur−/− mice 
Figure 6. Injection of high doses of recombinant mouse suPAR into uPAR-knockout (Plaur−/−) mouse 
model induces down-regulation of nephrin expression. (a) Quantification (left panel) of the ratio between 
urine total protein (mg)/creatinine (mg) concentration of suPAR treated mice with high dose of 20 μ g of 
mouse recombinant for 24 hours vs control mice (Mock) (N = 3 mice for group). Immune-fluorescence in 
green (right panel) of suPAR (488 Alexa Fluor) deposit into glomerular tissue of suPAR treated Plaur−/− 
mice. (b) Quantification (left panel) of immunoflourescence staining of nephrin and synaptopodin 
expression in Mock and suPAR treated mice. (N = 3 mice for group). DAPI staining was used to determine 
cell numbers. Data are expressed as average of MFI/cell ± SD. Representative immunoflourescence staining 
(right panel) of nephrin in green (488 Alexa Fluor), synaptopodin in red (594 Alexa Fluor) and nucleus in 
blue (DAPI) expression in untreated (Mock) and suPAR treated mice (N = 3 mice for group). (c) QPCR 
analysis of nephrin and WT-1 expression in Mock and suPAR treated mice obtained by using specific mice 
TaqMan assays and expressed as relative fold change ± SD vs. mock cells. (N = 3 mice for group). Statistical 
significance (P) is indicated by asterisks and is represented as: *< 0.05; **< 0.01; ***< 0.001.
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(Fig.  6c). These data demonstrate that suPAR is able to activate a specific repressor-signaling pathway 
that leads to suppression of WT-1 and Nephrin genes.
Discussion
Recently scientific opinion hailed the discovery of suPAR as a possible pathogenic factor as well as a 
mere biomarker of FSGS8. In addition different clinical studies observed increased suPAR concentration 
in various glomerular diseases thus implying on one hand the non specific role of suPAR in FSGS and 
on the other hand its emerging active pathological role in different glomerular and proteinuric unrelated 
to FSGS, disorders8–13. Indeed, in all studied renal disorders, increased suPAR was inversely associated 
to estimate glomerular filtration rate (eGFR) and in some reports to proteinuria. Nephritic syndromes 
represent characteristic clinical features also of other human diseases such as HIV and Hantavirus infec-
tion, diabetes and cardiovascular disorders that have been associated with increased level of suPAR14,46–52. 
Experimental studies both in vitro and in vivo clearly demonstrated the effect of suPAR on α vβ 3 integrin 
activation in podocytes8,33. In addition, studies using the Plaur−/− mice model confirmed the ability of 
high dose of suPAR to induce proteinuria8. Our study demonstrated that full length suPAR induced 
selective down-modulation of nephrin expression in human podocytes via interaction with α Vβ 3 integ-
rin. This negative regulation of nephrin was observed both at the protein and the transcriptional levels, 
and was associated with a reduced level of the transcription factor WT-1. Furthermore, in the in vivo 
suPAR knock out Plaur−/− mice model, the infusion of a high dose of suPAR correlates with lower 
expressions of nephrin and WT-1 in podocytes and glomerular permeability. Controversial results were 
obtained in wild type mice infused with high dose of suPAR53. These observations suggest that different 
molecular mechanism(s) may be involved in the detrimental action of suPAR in kidney physiopathology 
and various factors may control, inhibit or emphasize the toxic action of suPAR in pathological condi-
tions. In this context, expression of α vβ 3 integrin, which is expressed at low levels in podocytes under 
physiological conditions and increases in some pathologies, such as diabetic nephropathy, could play an 
important role54,55. Activation of α vβ 3 integrin in podocytes can be also inhibited by other integrins such 
as α 3β 1 that represents the principal integrin expressed in podocytes and interacts with glomerular base-
ment membrane30 .On the other hand, an α vβ 3 genetic polymorphism or other circulating factors such 
as TNF-α may affect suPAR activity56,57. Finally, the heterogeneity of circulating suPAR isoforms might 
explain why this biomarker, although being elevated in a variety of diseases, lacks disease-specificity 
and shows heterogeneous pathogenic action2. Besides the full length and cleaved form of suPAR various 
glycosylated variants of suPAR among different cell types have been reported2.Here, we show that only 
the full-length suPAR, but not c-suPAR, induces the down-modulation of nephrin, providing a concep-
tual framework for its pathogenetic action on podocytes in different human pathologies characterized 
by elevated suPAR and opening new therapeutic perspectives in the field. As an example, it might be 
interesting to evaluate the possible pathogenic role of suPAR in HIV infection since one of the clinical 
manifestation of kidney disorders in HIV pathogenesis is FSGS and increased levels of plasma suPAR 
in HIV patients have been correlated with disease progression14,58,59. Lymphoid organs of HIV infected 
individuals showed as an important site of production and release of suPAR and in particular full-length 
suPAR was found to be increased and contributes to prevent the anti-HIV activity of uPA6,14,60,61. In addi-
tion, we observed that plasma from HIV-infected individuals with increased levels of plasma suPAR have 
potential to induce downmodulation of nephrin (unpublished observation) and thus implicate suPAR as 
a possible renal risk factor in HIV pathogenesis.
Methods
Isolation and culture of human podocytes. Human renal tissue was obtained at the Department of 
Urology, Istituto Clinico Humanitas (Milan, Italy) from patients that underwent to both laparoscopic or 
open radical nephrectomy due to the renal cell carcinoma. All patients participated in this study provided 
written informed consent. All experimental protocols were approved by IRB (Authorization nr. 794/2011 
Ethic Committee, Humanitas Clinical and Research Center, Milan). All methods were carried out in 
accordance with the approved guidelines. All tissues were collected from the distal area of the patholog-
ical tissue and macroscopically free from any disease as verified by haematoxylin-eosin-staining. Under 
aseptic conditions kidneys were minced into small pieces and then pressed through a series of stainless 
steel sieves (sieving method) with decreasing pore size of 200-μ m, 100-μ m and 75-μ m. As a final step 
the glomeruli were collected on 75-μ m sieve, washed twice and cultured in collagen IV (Sigma-Aldrich), 
coated plates in F-12 medium (Sigma-Aldrich) with 10% FBS, 2 mM ultra-glutamine, 100 U/mL peni-
cillin, 100 μ g/mL streptomycin, nonessential aminoacids (all purchased from Lonza Verviers Sprl) and 
supplemented with insulin-transferrin-sodium-selenite media supplement (100X, Sigma-Aldrich) and 
0.35 ng/mL hydrocortisone (Sigma-Aldrich). After 3–4 days non attached glomeruli were washed and 
cultured for another 5–10 days. Conditionally immortalized human podocytes (CIHPs, kind gift from 
Dr. M. A. Saleem) were developed from primary human podocytes by transfection with the tempera-
ture-sensitive SV40-T and cultured as described in Saleem M.A. et al.34.
Reagents. Human full length suPAR (composed of the three domains DI, DII and DIII) and truncated 
suPAR (c-suPAR, composed of the two domains DII and DIII) were purified as previously described62, 
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and kindly provided by Dr. Massimo Resnati. RGDfv was purchased from Sigma-Aldrich (Saint Luis, 
MO, USA).
QPCR. Total RNA was extracted using RNeasy mini columns (Qiagen, Valencia, CA), following man-
ufacturer’s instructions, and its concentration was determined by spectrophotometry. One μ g of total 
RNA was used to generate cDNA templates for RT-PCR, using random primers, RNase inhibitor and 
High-Capacity cDNA Reverse Transcription Kit from Applied Biosystem (Foster City, CA). All mouse 
and human gene expression were analyzed by the Taqman® mRNA specific assays for: nephrin, podocin, 
synaptopodin, WT-1, Snail and GAPDH (Applied Biosystem).
Immunofluorescence. Human kidney tissue embedded and frozen in OCT or cells grown on cov-
erslips coated with human collagen IV were fixed with 4% paraformaldehyde (PFA) then washed, and 
immunolabeled over night at 4 °C with rabbit polyclonal anti-nephrin (clone Y17-R, Acris Antibodies, 
San Diego, CA, USA) or rabbit polyclonal anti-α vβ 3-integrin (clone 23C6, Santa Cruz) Ab. The bound 
antibody was stained with FITC/Alexa Fluor 594-conjugated goat anti-rabbit Ab respectively. Mouse 
kidney tissue embedded and frozen in OCT were fixed in acetone and stained for anti-nephrin (clone 
Y17-R) and subsequently with anti-synaptopodin (clone G1D4) followed by staining with FITC/Alexa 
Fluor 594-conjugated goat anti-rabbit and anti-mouse Ab respectively. SuPAR deposits in glomeruli were 
detected in frozen kidney tissue, fixed with 4% PFA and stained with antibody against murine uPAR 
(si420), kindly provided by Dr. Nicolai Sidenius (IFOM-IEO, Milan, Italy). Nuclei were stained with 
DAPI.
suPAR knock out Plaur−/− mice model. UPAR knock-out (Plaur−/−) mice63 were kindly provided 
by Dr. Nicolai Sidenius (IFOM-IEO, Milan, Italy) and maintained on C57BL6/N genetic background 
under specific pathogen-free conditions. Eight to ten week-old Plaur−/− mice were intravenously injected 
with 20 μ g (1 mg/Kg) of murine recombinant full length suPAR (R&D system). Twenty-four hours after 
injections, urine were collected and analyzed for creatinine and total protein content. Animals were then 
sacrificed and kidneys were collected and stored in OCT for immune fluorescence analyses and RNA 
extraction. Animal experiments adhered to the requirements of the Commission Directive 86/609/EEC 
and to the Italian legislation (Decreto Legislativo 116; 27 January 1992). All experimental protocols were 
approved by the Animal Care and Use Committee (Authorization nr. 192/2012-B, Humanitas Clinical and 
Research Center, Milan, Italy). All methods were carried out in accordance with the approved guidelines.
Chromatin Immunoprecipitation. Chromatin immunoprecipitation (ChIP) assays were performed 
with the use of EZ-Magna ChIP Chromatin Immunoprecipitation Kit (Millipore) following manufac-
turer’s instructions. CIHPs were growth at 80–90% of confluency. Jurkat and K562 cell lines (ATCC) 
were cultured in RPMI 1640 medium supplemented with 10% FBS, 2 mM ultra-glutamine, 100 U/mL 
penicillin, 100 μ g/mL streptomycin at concentration of 2 × 106 cells/mL. Protein-DNA complexes were 
cross linked with 1% formaldehyde followed by glycine 0.125 M treatment, then cells were harvested 
and nuclear extraction was performed. Nuclei were collected by centrifugation at 12000 g and were sus-
pended in sonication buffer with protease inhibitor cocktail and sheared to an average length of 750 bp 
by using Bioruptor Plus UCD-300 on high power for 36 cycles (30’’ ON and 30’’ OFF). Aliquots of 
cross-linked chromatin (50 uL) were diluted with 450 uL of ChIP dilution buffer and incubated over-
night at 4 °C with 20 uL protein A/G magnetic beads and 5.0 μ g/mL of rabbit polyclonal ChIP grade 
anti-WT-1 antibody (clone-C19, Santa Cruz Biotechnology). Mouse monoclonal anti-RNA polymerase 
II (CTD4H8) as the positive control was used and mouse/rabbit normal IgG were used as negative 
controls. 1% of non immunoprecipitated chromatin was saved as input sample. Cross-links between 
proteins and DNA were reversed by addition of ChIP elution buffer with proteinase K and incubation 
at 65 °C. DNA was purified using spin columns. Quantitative amplification of precipitated DNA frag-
ments was performed on a 7900HT Fast Real-Time System (Applied Biosystem) using SYBR Green 
assay. The following primer pairs were used Nphs1 promoter: 5′ CGCCCAGTCTCTTTATCTTTC–3′ , 
5′ –GACAAGGAGCAGGAGTGAG– 3′ ; GAPDH promoter: 5′ –TACTAGCGGTTTTACGGGCG–3′ , 5′ –
CGAACAGGAGGAGCAGAGAGCGA-3′ . The specificity of anti-WT-1 antibody used for ChIP assay 
was tested in Western blotting assay. All Inputs and chromatin immunoprecipitated samples with IgG 
or with anti-WT-1 rabbit polyclonal antibody (clone-C19, Santa Cruz Biotechnology) were separated by 
SDS-PAGE and transferred to nitrocellulose membrane. The membrane was blocked in 5% milk, incu-
bated overnight at 4 °C with the goat polyclonal anti-WT-1 primary antibodies (Abcam, ab96792) or goat 
polyclonal anti-β -actin (clone C-11, Santa-Cruz Biotechnology, Santa Cruz, CA, USA), washed and incu-
bated with secondary Ab -conjugated with horseradish peroxidase. Western blot analysis was conducted 
according to standard procedures using Immun-StarTM WesternCTM chemiluminescence detection sub-
strate kit (Bio-Rad, Hercules, CA, USA).
Statistical analysis. The significance of the data was assessed using ANOVA statistical analysis. Data 
shown are means ± S.D. The number of experiments is specified in the Figure legends. In the Figure 
statistical significance is indicated by asterisks (*). *P < 0.05; **P < 0.01; ***P < 0.001.
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